HER-2 positive and p53 negative breast cancers are associated with poor prognosis.

Hdl Handle:
http://hdl.handle.net/10147/207086
Title:
HER-2 positive and p53 negative breast cancers are associated with poor prognosis.
Authors:
Al-azawi, Dhafir; Leong, Sum; Wong, Limy; Kay, Elaine; Hill, Arnold D K; Young, Leonie
Affiliation:
Department of Surgery, Beaumont Hospital, Dublin, Ireland. dalazawi@rcsi.ie
Citation:
Cancer Invest. 2011 Jun;29(5):365-9.
Journal:
Cancer investigation
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207086
DOI:
10.3109/07357907.2011.584586
PubMed ID:
21599513
Abstract:
p53 and HER-2 coexpression in breast cancer has been controversial. These markers were tested using immunohistochemistry and HercepTest. HER-2 expression is related to reduced breast cancer survival (p = .02) . p53 expression relates to HER-2 expression (p = .029). Coexpression between p53 and HER-2 has no relation to prognosis. On univariate and multivariate analysis, combination of HER-2 positive and p53 negative expression was associated with a poor prognosis (p = .018 and p = .027, respectively), while the combination of HER-2 negative and p53 positive expression was associated with a favorable prognosis (p = .022 and p = .010, respectively). Therefore the expression of these markers should be considered collectively.
Language:
eng
MeSH:
Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/*chemistry/mortality/pathology/therapy; Chemotherapy, Adjuvant; Female; Humans; Immunohistochemistry; Ireland; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Receptor, erbB-2/*analysis; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Time Factors; Treatment Outcome; Tumor Markers, Biological/*analysis; Tumor Suppressor Protein p53/*analysis
ISSN:
1532-4192 (Electronic); 0735-7907 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorAl-azawi, Dhafiren_GB
dc.contributor.authorLeong, Sumen_GB
dc.contributor.authorWong, Limyen_GB
dc.contributor.authorKay, Elaineen_GB
dc.contributor.authorHill, Arnold D Ken_GB
dc.contributor.authorYoung, Leonieen_GB
dc.date.accessioned2012-02-01T09:58:52Z-
dc.date.available2012-02-01T09:58:52Z-
dc.date.issued2012-02-01T09:58:52Z-
dc.identifier.citationCancer Invest. 2011 Jun;29(5):365-9.en_GB
dc.identifier.issn1532-4192 (Electronic)en_GB
dc.identifier.issn0735-7907 (Linking)en_GB
dc.identifier.pmid21599513en_GB
dc.identifier.doi10.3109/07357907.2011.584586en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207086-
dc.description.abstractp53 and HER-2 coexpression in breast cancer has been controversial. These markers were tested using immunohistochemistry and HercepTest. HER-2 expression is related to reduced breast cancer survival (p = .02) . p53 expression relates to HER-2 expression (p = .029). Coexpression between p53 and HER-2 has no relation to prognosis. On univariate and multivariate analysis, combination of HER-2 positive and p53 negative expression was associated with a poor prognosis (p = .018 and p = .027, respectively), while the combination of HER-2 negative and p53 positive expression was associated with a favorable prognosis (p = .022 and p = .010, respectively). Therefore the expression of these markers should be considered collectively.en_GB
dc.language.isoengen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAgeden_GB
dc.subject.meshAged, 80 and overen_GB
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols/therapeutic useen_GB
dc.subject.meshBreast Neoplasms/*chemistry/mortality/pathology/therapyen_GB
dc.subject.meshChemotherapy, Adjuvanten_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHumansen_GB
dc.subject.meshImmunohistochemistryen_GB
dc.subject.meshIrelanden_GB
dc.subject.meshKaplan-Meier Estimateen_GB
dc.subject.meshMastectomyen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshNeoplasm Stagingen_GB
dc.subject.meshProportional Hazards Modelsen_GB
dc.subject.meshReceptor, erbB-2/*analysisen_GB
dc.subject.meshRecurrenceen_GB
dc.subject.meshRetrospective Studiesen_GB
dc.subject.meshRisk Factorsen_GB
dc.subject.meshSurvival Rateen_GB
dc.subject.meshTime Factorsen_GB
dc.subject.meshTreatment Outcomeen_GB
dc.subject.meshTumor Markers, Biological/*analysisen_GB
dc.subject.meshTumor Suppressor Protein p53/*analysisen_GB
dc.titleHER-2 positive and p53 negative breast cancers are associated with poor prognosis.en_GB
dc.contributor.departmentDepartment of Surgery, Beaumont Hospital, Dublin, Ireland. dalazawi@rcsi.ieen_GB
dc.identifier.journalCancer investigationen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.